What is the current valuation of the market in 2025?

The market valuation stands at 46.22 USD Billion as of 2024. Read More

What is the projected market size for the market by 2035?

The market is expected to reach 278.42 USD Billion by 2035. Read More

What is the expected CAGR for the China biologics market during the forecast period 2025 - 2035?

The anticipated CAGR is 17.73% from 2025 to 2035. Read More

Which segment of the China biologics market had the highest valuation in 2024?

Monoclonal Antibodies led the market with a valuation of 15.0 USD Billion. Read More

What is the projected valuation for the Vaccines segment by 2035?

The Vaccines segment is projected to reach 60.0 USD Billion by 2035. Read More

Which application segment is expected to grow the most in the China biologics market?

Neurological Disorders, valued at 16.3 USD Billion in 2024, is likely to see substantial growth. Read More

What is the market size for pharmaceutical companies as end users in 2024?

Pharmaceutical Companies accounted for 20.0 USD Billion in 2024. Read More

How does the market for recombinant proteins compare to that of hormones in 2024?

Recombinant Proteins were valued at 12.0 USD Billion, significantly higher than Hormones at 4.22 USD Billion. Read More

Which source type is projected to have the highest market valuation by 2035?

Mammalian sources are expected to reach 150.0 USD Billion by 2035. Read More

Who are the key players in the China biologics market?

Key players include AbbVie, Roche, Amgen, Johnson & Johnson, Novartis, Pfizer, Merck & Co., Bristol-Myers Squibb, and Gilead Sciences. Read More

China Biologics Market

ID: MRFR/HC/43091-HCR

200 Pages

Nidhi Mandole

Last Updated: May 07, 2026

China Biologics Market Research Report By Product Service (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others) and By Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others) - Growth & Industry Forecast 2025 To 2035

China Biologics Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)17.73%

2024 Market Size$ 46.22 Billion

2025 Market Size$ 54.41 Billion

2035 Market Size$ 278.42 Billion

Key Players

Companies such as AbbVie

Roche

Amgen

Johnson & Johnson

Novartis

Pfizer

Trends

Personalized Medicine
Collaborative Innovations
Rise of Biosimilars

Opportunities

Expanding Healthcare Infrastructure
Rising Investment in Biotech Startups
Increasing Demand for Targeted Therapies

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Chemicals and Materials, BY Type (USD Billion) | |
  1. 4.1.1 Monoclonal Antibodies | |
  2. 4.1.2 Vaccines | |
  3. 4.1.3 Cell and Gene Therapy | |
  4. 4.1.4 Recombinant Proteins | |
  5. 4.1.5 Hormones |
2. 4.2 Chemicals and Materials, BY Application (USD Billion) | |
  1. 4.2.1 Oncology | |
  2. 4.2.2 Infectious Diseases | |
  3. 4.2.3 Autoimmune Disorders | |
  4. 4.2.4 Cardiovascular Diseases | |
  5. 4.2.5 Neurological Disorders |
3. 4.3 Chemicals and Materials, BY End User (USD Billion) | |
  1. 4.3.1 Hospitals | |
  2. 4.3.2 Pharmaceutical Companies | |
  3. 4.3.3 Research Institutes | |
  4. 4.3.4 Diagnostics Laboratories |
4. 4.4 Chemicals and Materials, BY Source (USD Billion) | |
  1. 4.4.1 Microbial | |
  2. 4.4.2 Mammalian | |
  3. 4.4.3 Plant | |
  4. 4.4.4 Transgenic Animals 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AbbVie (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Roche (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Amgen (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Johnson & Johnson (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Novartis (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Pfizer (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Merck & Co. (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Bristol-Myers Squibb (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Gilead Sciences (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 CHINA MARKET ANALYSIS BY TYPE |
6. 6.3 CHINA MARKET ANALYSIS BY APPLICATION |
7. 6.4 CHINA MARKET ANALYSIS BY END USER |
8. 6.5 CHINA MARKET ANALYSIS BY SOURCE |
9. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS |
12. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS |
14. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS |
15. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE) |
16. 6.13 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Billion) |
17. 6.14 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE) |
18. 6.15 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Billion) |
19. 6.16 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE) |
20. 6.17 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Billion) |
21. 6.18 CHEMICALS AND MATERIALS, BY SOURCE, 2024 (% SHARE) |
22. 6.19 CHEMICALS AND MATERIALS, BY SOURCE, 2024 TO 2035 (USD Billion) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY SOURCE, 2025-2035 (USD Billion) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

China Biologics Market Segmentation

China Biologics Market By Type (USD Billion, 2025-2035)

Monoclonal Antibodies
Vaccines
Cell and Gene Therapy
Recombinant Proteins
Hormones

China Biologics Market By Application (USD Billion, 2025-2035)

Oncology
Infectious Diseases
Autoimmune Disorders
Cardiovascular Diseases
Neurological Disorders

China Biologics Market By End User (USD Billion, 2025-2035)

Hospitals
Pharmaceutical Companies
Research Institutes
Diagnostics Laboratories

China Biologics Market By Source (USD Billion, 2025-2035)

Microbial
Mammalian
Plant
Transgenic Animals

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”